Proprietary Research

News Articles for Proprietary Research top ^
Cigna (NYSE:CI) is launching its proprietary private retail exchange in new markets and expanding in others, offering employers a new, cost-effective way to give employees more benefit choices, all in one place.
Sign-up for Cigna’s Proprietary Retail Exchange Launches Nationally investment picks
TEL AVIV, Israel, June 17, 2014 (GLOBE NEWSWIRE) -- Ltd (Nasdaq:WIX) , a leading web development platform, announced that as a global company tackling the challenges of processing localized payments, it has developed its own proprietary billing system, enabling it to integrate with any local payment gateway and acquirer in the world.
Sign-up for Develops Proprietary Billing System to Support Global Expansion investment picks
In an industry first, Clear Channel Media and Entertainment (CCM+E) today launched the Audience Delivery Optimizer ( AuDiO ), a groundbreaking, proprietary radio targeting tool developed specifically for political advertisers.
Sign-up for Clear Channel Launches AuDiO, a Groundbreaking, Proprietary Radio Targeting Tool for Political Advertisers investment picks
2014/7/16 SCOTTSDALE, AZ--(Marketwired - July 16, 2014) - American Nortel Communications, Inc.: (PINKSHEETS: ARTM) today announces that, a wholly owned subsidiary of American Nortel Communications, Inc. releases its proprietary moving technology nationwide to 12,000 cities.
Sign-up for Releases Its Proprietary Moving Technology Nationwide to 12,000 Cities investment picks
Flexion secures expanded intellectual property for manufacturing of FX006 sustained- release microsphere drug candidate  License includes musculoskeletal disorders and several steroid microsphere combinations BURLINGTON, Mass., July 28, 2014 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it has executed an exclusive worldwide licensing agreement with SwRI to utilize proprietary microsphere manufacturing technologies for production of Flexion's sustained-release drug candidates, including leading candidate FX006.
Sign-up for Flexion Therapeutics and Southwest Research Institute(R) (SwRI(R)) Sign Worldwide Exclusive License for Proprietary Microsphere Manufacturing Technologies investment picks
Online database allows clinicians and patients to search for genetic and genomic tests by disease state Increases access to information about and awareness of Cancer Genetics' proprietary diagnostic tests RUTHERFORD, N.J., Aug.
Sign-up for Cancer Genetics' Proprietary Genomic Diagnostic Tests Added to National Institutes of Health's Genetic Testing Registry investment picks
Sign-up for Cancer Genetics' Proprietary IVD for Cervical Cancer, FHACT(R), Receives CE investment picks
BOSTON, July 10, 2014 (GLOBE NEWSWIRE) -- Verde Media Group Inc. (OTC:VMGI) , through its Verde Media Biotechnology Division ("VMBD") is preparing for the next phase of construction for its Pilot and semi-commercial Omega-3 oil production facility in Asia.
Sign-up for Verde Media Group Inc. to Launch Proprietary Deep Well Fermentation Technology for Omega-3 Production in Asia investment picks
PHOENIX , July 8, 2014 /PRNewswire/ -- New Media Insight Group, Inc. ("New Media" or "the Company") (OTCBB: NMED) , a leader in mobile payments, announced today that they are in the final development stages of a near field communication (NFC) payment solution and plan to launch it over the next three to four months.
Sign-up for New Media Insight Group Announces Upcoming Launch of Proprietary NFC Payment Solution investment picks DENVER, CO --
Sign-up for Blue Line Protection Group Launches Proprietary Financial Compliance Platform With First Security Bank of Nevada investment picks
- Patent will protect MYOS' intellectual property portfolio for Fortetropin through 2033 – CEDAR KNOLLS, N.J., July 24, 2014 (GLOBE NEWSWIRE) -- MYOS Corporation ("MYOS" or the "Company") (Nasdaq:MYOS) , an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and performance, announced today that it recently received a Notice of Allowance from the U.S. Patent and Trademark Office ("USPTO") for U.S. Patent Application Serial No.
Sign-up for MYOS Corporation Receives Notice of Allowance of U.S. Patent Application for Proprietary Manufacturing Methods of Fortetropin investment picks
Capsugel and Cardax, Inc. (“Cardax”) (OTCQB:CDXI) announced today a collaboration to develop unique astaxanthin products for the consumer health market.
Sign-up for Capsugel and Cardax to Collaborate on Development of Proprietary Astaxanthin Products investment picks

Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.


Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Proprietary Research
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Proposed Sale  |  Next: Prospective Resources